AAPL   329.23 (+2.14%)
MSFT   185.75 (+1.55%)
FB   230.62 (+1.91%)
AMZN   2,468.73 (+0.33%)
NVDA   354.61 (+1.13%)
BABA   220.01 (+0.90%)
MU   54.21 (+5.84%)
GE   8.22 (+6.07%)
AMD   52.54 (-0.17%)
T   32.87 (+3.37%)
ACB   13.84 (-2.74%)
F   7.41 (+12.80%)
NFLX   414.24 (-0.02%)
BAC   28.41 (+6.05%)
BA   215.73 (+17.05%)
AAPL   329.23 (+2.14%)
MSFT   185.75 (+1.55%)
FB   230.62 (+1.91%)
AMZN   2,468.73 (+0.33%)
NVDA   354.61 (+1.13%)
BABA   220.01 (+0.90%)
MU   54.21 (+5.84%)
GE   8.22 (+6.07%)
AMD   52.54 (-0.17%)
T   32.87 (+3.37%)
ACB   13.84 (-2.74%)
F   7.41 (+12.80%)
NFLX   414.24 (-0.02%)
BAC   28.41 (+6.05%)
BA   215.73 (+17.05%)
AAPL   329.23 (+2.14%)
MSFT   185.75 (+1.55%)
FB   230.62 (+1.91%)
AMZN   2,468.73 (+0.33%)
NVDA   354.61 (+1.13%)
BABA   220.01 (+0.90%)
MU   54.21 (+5.84%)
GE   8.22 (+6.07%)
AMD   52.54 (-0.17%)
T   32.87 (+3.37%)
ACB   13.84 (-2.74%)
F   7.41 (+12.80%)
NFLX   414.24 (-0.02%)
BAC   28.41 (+6.05%)
BA   215.73 (+17.05%)
AAPL   329.23 (+2.14%)
MSFT   185.75 (+1.55%)
FB   230.62 (+1.91%)
AMZN   2,468.73 (+0.33%)
NVDA   354.61 (+1.13%)
BABA   220.01 (+0.90%)
MU   54.21 (+5.84%)
GE   8.22 (+6.07%)
AMD   52.54 (-0.17%)
T   32.87 (+3.37%)
ACB   13.84 (-2.74%)
F   7.41 (+12.80%)
NFLX   414.24 (-0.02%)
BAC   28.41 (+6.05%)
BA   215.73 (+17.05%)
Log in

OTCMKTS:CYDYCytoDyn News Headlines

$2.85
-0.06 (-2.06 %)
(As of 06/5/2020 12:20 PM ET)
Add
Compare
Today's Range
$2.80
Now: $2.85
$2.91
50-Day Range
$2.25
MA: $2.97
$3.50
52-Week Range
$0.26
Now: $2.85
$3.84
Volume2.27 million shs
Average Volume5.65 million shs
Market Capitalization$1.47 billion
P/E RatioN/A
Dividend YieldN/A
Beta-0.63

Headlines

CytoDyn (OTCMKTS CYDY) News Headlines

Source:
DateHeadline
CytoDyn: COVID-19 Crunch Time - Seeking AlphaCytoDyn: COVID-19 Crunch Time - Seeking Alpha
seekingalpha.com - June 4 at 5:31 PM
CytoDyn gives Mulholland permanent CFO jobCytoDyn gives Mulholland permanent CFO job
seekingalpha.com - June 3 at 7:28 AM
CytoDyn Inc. 8-K Jun. 2, 2020 5:00 PM - Seeking AlphaCytoDyn Inc. 8-K Jun. 2, 2020 5:00 PM - Seeking Alpha
seekingalpha.com - June 2 at 8:19 PM
CytoDyn to Present at Wall Street Reporter’s Livestream Event on June 2, 2020 at 12:30 pm ET / 9:30 am PT - Yahoo FinanceCytoDyn to Present at Wall Street Reporter’s Livestream Event on June 2, 2020 at 12:30 pm ET / 9:30 am PT - Yahoo Finance
finance.yahoo.com - June 1 at 1:01 PM
CytoDyn requests for priority review of Leronlimab BLA for HIV - Seeking AlphaCytoDyn requests for priority review of Leronlimab BLA for HIV - Seeking Alpha
seekingalpha.com - June 1 at 8:01 AM
CytoDyn to Present at Wall Street Reporters Livestream Event on June 2, 2020 at 12:30 pm ET / 9:30 am PT - GlobeNewswireCytoDyn to Present at Wall Street Reporter's Livestream Event on June 2, 2020 at 12:30 pm ET / 9:30 am PT - GlobeNewswire
www.globenewswire.com - June 1 at 8:01 AM
CytoDyn Files Request With FDA for Priority Review of BLA for First ApprovalCytoDyn Files Request With FDA for Priority Review of BLA for First Approval
finance.yahoo.com - June 1 at 8:01 AM
CytoDyn to Present at Wall Street Reporter’s Livestream Event on June 2, 2020 at 12:30 pm ET / 9:30 am PTCytoDyn to Present at Wall Street Reporter’s Livestream Event on June 2, 2020 at 12:30 pm ET / 9:30 am PT
finance.yahoo.com - June 1 at 8:01 AM
CytoDyn to Hold Conference Call to Provide Updates on COVID-19 (Phase 2, 3 & eIND), Cancer (mTNBC, Phase 2 for 22 Solid Tumor Cancers), HIV (BLA, Monotherapy), NASH, GvHD and MS - Yahoo FinanceCytoDyn to Hold Conference Call to Provide Updates on COVID-19 (Phase 2, 3 & eIND), Cancer (mTNBC, Phase 2 for 22 Solid Tumor Cancers), HIV (BLA, Monotherapy), NASH, GvHD and MS - Yahoo Finance
finance.yahoo.com - May 23 at 3:15 AM
CytoDyn to Hold Conference Call to Provide Updates on COVID-19 (Phase 2, 3 & eIND), Cancer (mTNBC, Phase 2 for 22 Solid Tumor Cancers), HIV (BLA, Monotherapy), NASH, GvHD and MS - GlobeNewswireCytoDyn to Hold Conference Call to Provide Updates on COVID-19 (Phase 2, 3 & eIND), Cancer (mTNBC, Phase 2 for 22 Solid Tumor Cancers), HIV (BLA, Monotherapy), NASH, GvHD and MS - GlobeNewswire
www.globenewswire.com - May 22 at 10:01 PM
CytoDyn to Hold Conference Call to Provide Updates on COVID-19 (Phase 2, 3 & eIND), Cancer (mTNBC, Phase 2 for 22 Solid Tumor Cancers), HIV (BLA, Monotherapy), NASH, GvHD and MSCytoDyn to Hold Conference Call to Provide Updates on COVID-19 (Phase 2, 3 & eIND), Cancer (mTNBC, Phase 2 for 22 Solid Tumor Cancers), HIV (BLA, Monotherapy), NASH, GvHD and MS
finance.yahoo.com - May 22 at 10:01 PM
CytoDyn and the Mexican National Institutes of Health Participate in a Collaborative Study of Leronlimab for the Treatment of Severe/Critical COVID-19 Population - Yahoo FinanceCytoDyn and the Mexican National Institutes of Health Participate in a Collaborative Study of Leronlimab for the Treatment of Severe/Critical COVID-19 Population - Yahoo Finance
finance.yahoo.com - May 19 at 10:39 PM
CytoDyn and the Mexican National Institutes of Health Participate in a Collaborative Study of Leronlimab for the Treatment of Severe/Critical COVID-19 Population - GlobeNewswireCytoDyn and the Mexican National Institutes of Health Participate in a Collaborative Study of Leronlimab for the Treatment of Severe/Critical COVID-19 Population - GlobeNewswire
www.globenewswire.com - May 19 at 7:30 AM
CytoDyn and the Mexican National Institutes of Health Participate in a Collaborative Study of Leronlimab for the Treatment of Severe/Critical COVID-19 PopulationCytoDyn and the Mexican National Institutes of Health Participate in a Collaborative Study of Leronlimab for the Treatment of Severe/Critical COVID-19 Population
finance.yahoo.com - May 19 at 7:30 AM
CytoDyn to compare leronlimab to remdesivir in COVID-19 - Seeking AlphaCytoDyn to compare leronlimab to remdesivir in COVID-19 - Seeking Alpha
seekingalpha.com - May 18 at 1:20 PM
CytoDyn to Prepare a Phase 3 Protocol to Submit to the FDA for a Three-Arm Comparative and Combination Trial of Leronlimab and Remdesivir - Yahoo FinanceCytoDyn to Prepare a Phase 3 Protocol to Submit to the FDA for a Three-Arm Comparative and Combination Trial of Leronlimab and Remdesivir - Yahoo Finance
finance.yahoo.com - May 18 at 1:20 PM
CytoDyn to Prepare a Phase 3 Protocol to Submit to the FDA for a Three-Arm Comparative and Combination Trial of Leronlimab and RemdesivirCytoDyn to Prepare a Phase 3 Protocol to Submit to the FDA for a Three-Arm Comparative and Combination Trial of Leronlimab and Remdesivir
finance.yahoo.com - May 18 at 8:18 AM
CytoDyn to Offer No-Cost Exploratory Laboratory Testing for Childhood Inflammatory Disease Associated with COVID-19 - Yahoo FinanceCytoDyn to Offer No-Cost Exploratory Laboratory Testing for Childhood Inflammatory Disease Associated with COVID-19 - Yahoo Finance
finance.yahoo.com - May 15 at 9:57 AM
CytoDyn to Offer No-Cost Exploratory Laboratory Testing for Childhood Inflammatory Disease Associated with COVID-19CytoDyn to Offer No-Cost Exploratory Laboratory Testing for Childhood Inflammatory Disease Associated with COVID-19
finance.yahoo.com - May 15 at 9:57 AM
CytoDyn (CYDY) to Report Q4 Earnings: Whats in the Cards? - Yahoo FinanceCytoDyn (CYDY) to Report Q4 Earnings: What's in the Cards? - Yahoo Finance
finance.yahoo.com - May 14 at 6:28 PM
CytoDyn completes rolling U.S. application for leronlimab in HIV - Seeking AlphaCytoDyn completes rolling U.S. application for leronlimab in HIV - Seeking Alpha
seekingalpha.com - May 14 at 1:27 PM
CytoDyn (CYDY) to Report Q4 Earnings: Whats in the Cards?CytoDyn (CYDY) to Report Q4 Earnings: What's in the Cards?
www.nasdaq.com - May 13 at 5:25 PM
CytoDyn Completed Submission of All Remaining Parts of Biologics License Application (“BLA”) on May 11, 2020 - GlobeNewswireCytoDyn Completed Submission of All Remaining Parts of Biologics License Application (“BLA”) on May 11, 2020 - GlobeNewswire
www.globenewswire.com - May 13 at 7:24 AM
CytoDyn Completed Submission of All Remaining Parts of Biologics License Application (“BLA”) on May 11, 2020CytoDyn Completed Submission of All Remaining Parts of Biologics License Application (“BLA”) on May 11, 2020
finance.yahoo.com - May 13 at 7:24 AM
CytoDyn to Present at Wall Street Reporters NEXT SUPERSTOCK Livestream Event on May 13, 2020 at 12:30 pm ET / 9:30 am PT - GlobeNewswireCytoDyn to Present at Wall Street Reporter's NEXT SUPERSTOCK Livestream Event on May 13, 2020 at 12:30 pm ET / 9:30 am PT - GlobeNewswire
www.globenewswire.com - May 11 at 5:53 PM
CytoDyn to Present at Wall Street Reporter’s NEXT SUPERSTOCK Livestream Event on May 13, 2020 at 12:30 pm ET / 9:30 am PTCytoDyn to Present at Wall Street Reporter’s NEXT SUPERSTOCK Livestream Event on May 13, 2020 at 12:30 pm ET / 9:30 am PT
finance.yahoo.com - May 11 at 7:14 AM
CytoDyn: Matching Leronlimab Up Against Other COVID-19 Therapeutics - Seeking AlphaCytoDyn: Matching Leronlimab Up Against Other COVID-19 Therapeutics - Seeking Alpha
seekingalpha.com - May 11 at 2:14 AM
CytoDyn Clarifies Status of Biologics License Application - Yahoo FinanceCytoDyn Clarifies Status of Biologics License Application - Yahoo Finance
finance.yahoo.com - May 8 at 11:30 PM
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of CytoDyn Inc. (CYDY) on Behalf of Investors - Business WireGlancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of CytoDyn Inc. (CYDY) on Behalf of Investors - Business Wire
www.businesswire.com - May 8 at 6:29 PM
Federman & Sherwood Investigates CytoDyn Inc. for Possible Violations of Federal Securities Laws - Yahoo FinanceFederman & Sherwood Investigates CytoDyn Inc. for Possible Violations of Federal Securities Laws - Yahoo Finance
finance.yahoo.com - May 8 at 6:29 PM
SHAREHOLDER ALERT: Investigation of CytoDyn Announced by Holzer & Holzer, LLCSHAREHOLDER ALERT: Investigation of CytoDyn Announced by Holzer & Holzer, LLC
finance.yahoo.com - May 8 at 6:29 PM
Federman & Sherwood Investigates CytoDyn Inc. for Possible Violations of Federal Securities LawsFederman & Sherwood Investigates CytoDyn Inc. for Possible Violations of Federal Securities Laws
finance.yahoo.com - May 8 at 6:29 PM
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of CytoDyn Inc. (CYDY) on Behalf of InvestorsINVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of CytoDyn Inc. (CYDY) on Behalf of Investors
finance.yahoo.com - May 8 at 6:29 PM
The Law Offices of Frank R. Cruz Announces Investigation on Behalf of CytoDyn Inc. Investors (CYDY)The Law Offices of Frank R. Cruz Announces Investigation on Behalf of CytoDyn Inc. Investors (CYDY)
finance.yahoo.com - May 8 at 6:29 PM
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of CytoDyn Inc. (CYDY) on Behalf of InvestorsGlancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of CytoDyn Inc. (CYDY) on Behalf of Investors
finance.yahoo.com - May 8 at 6:29 PM
Novant Health Initiates Phase 2b/3 Trial with CytoDyn’s Leronlimab for Severely and Critically Ill COVID-19 PatientsNovant Health Initiates Phase 2b/3 Trial with CytoDyn’s Leronlimab for Severely and Critically Ill COVID-19 Patients
finance.yahoo.com - May 8 at 4:12 AM
Novant Health Initiates Phase 2b/3 Trial with CytoDyns Leronlimab for Severely and Critically Ill COVID-19 Patients - GlobeNewswireNovant Health Initiates Phase 2b/3 Trial with CytoDyn's Leronlimab for Severely and Critically Ill COVID-19 Patients - GlobeNewswire
www.globenewswire.com - May 7 at 11:12 PM
CytoDyns Answer To COVID-19 - Seeking AlphaCytoDyn's Answer To COVID-19 - Seeking Alpha
seekingalpha.com - May 7 at 6:11 PM
Manuscript Describes How CytoDyn’s Leronlimab Disrupts CCL5/RANTES-CCR5 Pathway, Thereby Restoring Immune Homeostasis, Reducing Plasma Viral Load, Reversing Hyper Immune Activation and Inflammation in Critical COVID-19 Patients - Yahoo FinanceManuscript Describes How CytoDyn’s Leronlimab Disrupts CCL5/RANTES-CCR5 Pathway, Thereby Restoring Immune Homeostasis, Reducing Plasma Viral Load, Reversing Hyper Immune Activation and Inflammation in Critical COVID-19 Patients - Yahoo Finance
finance.yahoo.com - May 6 at 2:02 PM
Manuscript Describes How CytoDyns Leronlimab Disrupts CCL5/RANTES-CCR5 Pathway, Thereby Restoring Immune Homeostasis, Reducing Plasma Viral Load, Reversing Hyper Immune Activation and Inflammation in Critical COVID-19 Patients - GlobeNewswireManuscript Describes How CytoDyn's Leronlimab Disrupts CCL5/RANTES-CCR5 Pathway, Thereby Restoring Immune Homeostasis, Reducing Plasma Viral Load, Reversing Hyper Immune Activation and Inflammation in Critical COVID-19 Patients - GlobeNewswire
www.globenewswire.com - May 6 at 4:26 AM
Manuscript Describes How CytoDyn’s Leronlimab Disrupts CCL5/RANTES-CCR5 Pathway, Thereby Restoring Immune Homeostasis, Reducing Plasma Viral Load, Reversing Hyper Immune Activation and Inflammation in Critical COVID-19 PatientsManuscript Describes How CytoDyn’s Leronlimab Disrupts CCL5/RANTES-CCR5 Pathway, Thereby Restoring Immune Homeostasis, Reducing Plasma Viral Load, Reversing Hyper Immune Activation and Inflammation in Critical COVID-19 Patients
finance.yahoo.com - May 6 at 4:26 AM
Ajinomoto Bio-Pharma Services annonce un partenariat de fabrication avec CytoDyn concernant un médicament utilisé dans les essais cliniques contre le COVID-19Ajinomoto Bio-Pharma Services annonce un partenariat de fabrication avec CytoDyn concernant un médicament utilisé dans les essais cliniques contre le COVID-19
www.prnewswire.com - May 5 at 8:27 AM
Ajinomoto Bio-Pharma Services gibt Partnerschaft mit CytoDyn für Fertigung von Medikamenten bekannt, die in klinischen Studien zu COVID-19 verwendet werdenAjinomoto Bio-Pharma Services gibt Partnerschaft mit CytoDyn für Fertigung von Medikamenten bekannt, die in klinischen Studien zu COVID-19 verwendet werden
www.prnewswire.com - May 5 at 8:27 AM
Ajinomoto Bio-Pharma Services Announces Manufacturing Partnership with CytoDyn for Drug Product Used in COVID-19 Clinical Trials - PRNewswireAjinomoto Bio-Pharma Services Announces Manufacturing Partnership with CytoDyn for Drug Product Used in COVID-19 Clinical Trials - PRNewswire
www.prnewswire.com - May 5 at 8:17 AM
“Next Super Stocks” in News: fuboTV (OTC: FUBO) Edgar Bronfman, Jr. Appointed Executive Chairman - CytoDyn (OTC: CYDY) Reports Strong Results From COVID-19 Coronavirus Patients Treated with Leronlimab - NexTech AR Solutions (OTC: NEXCF) Acquires Remote Work/Learning App with Blue Chip Customer Base - Yahoo Finance“Next Super Stocks” in News: fuboTV (OTC: FUBO) Edgar Bronfman, Jr. Appointed Executive Chairman - CytoDyn (OTC: CYDY) Reports Strong Results From COVID-19 Coronavirus Patients Treated with Leronlimab - NexTech AR Solutions (OTC: NEXCF) Acquires Remote Work/Learning App with Blue Chip Customer Base - Yahoo Finance
finance.yahoo.com - May 4 at 5:15 PM
“Next Super Stocks” in News: fuboTV (OTC: FUBO) Edgar Bronfman, Jr. Appointed Executive Chairman -  CytoDyn (OTC: CYDY) Reports Strong Results From COVID-19 Coronavirus Patients Treated with Leronlimab - NexTech AR Solutions (OTC: NEXCF) Acquires  Remote Work/Learning App with Blue Chip Customer Base“Next Super Stocks” in News: fuboTV (OTC: FUBO) Edgar Bronfman, Jr. Appointed Executive Chairman -  CytoDyn (OTC: CYDY) Reports Strong Results From COVID-19 Coronavirus Patients Treated with Leronlimab - NexTech AR Solutions (OTC: NEXCF) Acquires  Remote Work/Learning App with Blue Chip Customer Base
finance.yahoo.com - May 4 at 5:15 PM
FDA Approves 54 Emergency INDs for Leronlimab Treatment of Coronavirus – CytoDyn Requests Compassionate Use from FDA for COVID-19 Patients Not Eligible for Participation in Two Ongoing Clinical Trials in U.S. – CytoDyn Targets Enrollment Completion for its 75 Patient, Phase 2 Trial by End of May - GlobeNewswireFDA Approves 54 Emergency INDs for Leronlimab Treatment of Coronavirus – CytoDyn Requests Compassionate Use from FDA for COVID-19 Patients Not Eligible for Participation in Two Ongoing Clinical Trials in U.S. – CytoDyn Targets Enrollment Completion for its 75 Patient, Phase 2 Trial by End of May - GlobeNewswire
www.globenewswire.com - May 4 at 6:36 AM
FDA Approves 54 Emergency INDs for Leronlimab Treatment of Coronavirus – CytoDyn Requests Compassionate Use from FDA for COVID-19 Patients Not Eligible for Participation in Two Ongoing Clinical Trials in U.S. – CytoDyn Targets Enrollment Completion for its 75 Patient, Phase 2 Trial by End of MayFDA Approves 54 Emergency INDs for Leronlimab Treatment of Coronavirus – CytoDyn Requests Compassionate Use from FDA for COVID-19 Patients Not Eligible for Participation in Two Ongoing Clinical Trials in U.S. – CytoDyn Targets Enrollment Completion for its 75 Patient, Phase 2 Trial by End of May
finance.yahoo.com - May 4 at 6:36 AM
Experimental coronavirus treatment leronlimab resulted in remarkable recoveries, developer says - Fox NewsExperimental coronavirus treatment leronlimab resulted in 'remarkable recoveries,' developer says - Fox News
www.foxnews.com - May 1 at 4:38 PM
CytoDyn Issues Update On COVID-19 Patients Receiving Leronlimab Under EINDs - NasdaqCytoDyn Issues Update On COVID-19 Patients Receiving Leronlimab Under EINDs - Nasdaq
www.nasdaq.com - April 30 at 6:19 PM
This page was last updated on 6/5/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.